JUBILANT PHARMOVA LIMITED
₹924.70-₹17.70 (-1.9%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹16,581 Cr
- EV / EBITDA
- 140.4x
- Revenue
- ₹746 Cr
- Net margin
- 4.1%
- ROCE
- 0.7%
Price chart
Technical chartScreen technicals →-17.4% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -10.1%
- 3M
- -3.8%
- 6M
- -0.2%
- 1Y
- -17.4%
- 5Y
- +51.7%
52-week range
Day change -₹17.70 (-1.9%) from ₹942 to ₹925 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in JUBLPHARMA, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Maintains healthy dividend payout of 252.0%
Concerns1
- Low interest coverage ratio of 0.6x
Rule-based from financial data. Not advice.
About the company
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs.
Read moreShow less
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. The company serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.
- Sector
- Healthcare
- Shares outstanding
- 15.9 Cr shares
- ISIN
- INE700A01033
- BSE code
- 530019
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹16,581 Cr
- P/B
- 7.4x
- EV / EBITDA
- 140.4x
- EV / Sales
- 21.5x
- P/S
- 21.1x
- 52-week high
- ₹1,181.25
- 52-week low
- ₹808.90
Profitability
- Operating margin
- 2.3%
- Net margin
- 4.1%
- EBITDA margin
- 15.3%
- ROE
- 1.3%
- ROCE
- 0.7%
- ROA
- 1.1%
- Dividend payout
- 252.0%
- Tax rate
- 24.0%
- Other income, % of PBT
- 242.9%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹746 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -5.0%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -24.2%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹120 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -14.9%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -40.6%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -36.9%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹143 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -320.0%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹24.0 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -0.5%
Solvency and efficiency
- Current ratio
- 9.47
- Debt / Equity
- 0.16
- Debt / Assets
- 0.13
- Debt / EBITDA
- 3.17
- Interest coverage
- 0.60
- Financial leverage
- 1.26
- CFO / Net profit
- 4.47
- Cash / Market cap
- 3.5%
- Cash per share
- ₹36.85
- Asset turnover
- 0.26
- Fixed asset turnover
- 1.10
- Capital intensity
- 0.91
- Debtor days
- 90 days
- Inventory turnover
- 1.41
- Cash conversion cycle
- 196 days
Where the revenue went
Some FY2025 lines are not reported, so the ones that are appear as a table.
| Line | FY2025 |
|---|---|
| Sales | ₹746 Cr |
| Expenses | ₹714 Cr |
| Operating profit | ₹32 Cr |
| Other income | ₹88 Cr |
| Interest | ₹30 Cr |
| Depreciation | ₹53 Cr |
| Profit before tax | ₹38 Cr |
| Tax and other | ₹19 Cr |
| Net profit | ₹19 Cr |
Revenue and net profit
Revenue fell 5.0% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹2,710 Cr | ₹214 Cr |
| FY2022 | ₹726 Cr | ₹80 Cr |
| FY2023 | ₹810 Cr | ₹50 Cr |
| FY2024 | ₹785 Cr | ₹32 Cr |
| FY2025 | ₹746 Cr | ₹19 Cr |
Cash flows
FY2025: ₹136 Cr from operations, ₹134 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹608 Cr | ₹786 Cr |
| FY2022 | -₹4 Cr | ₹89 Cr |
| FY2023 | -₹65 Cr | -₹34 Cr |
| FY2024 | ₹143 Cr | ₹103 Cr |
| FY2025 | ₹136 Cr | ₹134 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹746 Cr-5.0%1Y
- Net profit
- ₹19 Cr-40.6%1Y
- Cash from operations
- ₹136 Cr
- Free cash flow
- ₹134 Cr+30.1%1Y
- Revenue CAGR, 5Y
- -24.2%
- EBITDA CAGR, 5Y
- -26.1%
- Net profit CAGR, 5Y
- -36.9%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹746 Cr | ₹32 Cr | — | ₹19 Cr | ₹136 Cr | ₹134 Cr | 0.8% | -5.0% | -40.6% |
Monthly returns
Month-by-month returns of JUBLPHARMA across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹2,910 Cr |
| Equity capital | ₹16 Cr |
| Reserves | ₹2,302 Cr |
| Borrowings | ₹336 Cr |
| Other liabilities | ₹255 Cr |
| Assets | ₹2,910 Cr |
| Fixed assets | ₹699 Cr |
| Capital work in progress | ₹19 Cr |
| Investments | ₹1,657 Cr |
| Other assets | ₹535 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
JUBLPHARMA has no positive P/E; the peer median is 52.6x.
Not shown (no positive earnings and no EV / Sales): JUBILANT PHARMOVA LIMITED.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| JUBILANT PHARMOVA LIMITEDJUBLPHARMAthis company | ₹16,581 Cr | — | 7.4x | 1.3% | 140.4x |
| Sai Life Sciences LimitedSAILIFE | ₹19,113 Cr | 67.7x | 8.2x | 9.4% | 62.4x |
| Neuland Laboratories Limited.NEULANDLAB | ₹18,376 Cr | 94.3x | 11.4x | 23.5% | 38.6x |
| Ventive Hospitality LimitedVENTIVE | ₹17,846 Cr | 91.9x | 3.9x | 49.7% | 60.7x |
| Poly Medicure LtdPOLYMED | ₹17,352 Cr | 49.8x | 6.0x | 17.3% | 42.5x |
| Cohance Lifesciences LimitedCOHANCE | ₹17,161 Cr | 46.3x | 3.9x | 14.6% | 37.0x |
| Dr. Agarwal's Health Care LimitedAGARWALEYE | ₹15,850 Cr | 302.0x | 8.1x | 2.0% | 62.8x |
| ALEMBIC PHARMACEUTICALS LIMITEDAPLLTD | ₹15,765 Cr | 35.5x | 3.0x | 13.6% | 15.2x |
| Natco Pharma Ltd.NATCOPHARM | ₹15,582 Cr | 10.3x | 1.9x | 23.4% | 8.8x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
JUBLPHARMA since 1 January, against earlier years.
Historical volatility
JUBLPHARMA's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 16.0% |
| FY2022 | 1.0% |
| FY2023 | 0.0% |
| FY2024 | 2.0% |
| FY2025 | 4.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹746 Cr |
| Costs | |
| Interest | ₹30 Cr |
| Expenses | ₹714 Cr |
| Operating profitOperating Profit | ₹32 Cr |
| Other income and charges | |
| Profit before tax | ₹38 Cr |
| Tax | |
| Net profitNet Profit | ₹19 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹2,910 Cr |
| Equity capitalEquity Capital | ₹16 Cr |
| Reserves | ₹2,302 Cr |
| Borrowings | ₹336 Cr |
| Other liabilitiesOther Liabilities | ₹255 Cr |
| AssetsTotal Assets | ₹2,910 Cr |
| Fixed assetsFixed Assets | ₹699 Cr |
| Capital work in progressCWIP | ₹19 Cr |
| Investments | ₹1,657 Cr |
| Other assetsOther Assets | ₹535 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹136 Cr |
| Investing cash flowCash from Investing Activity | -₹2 Cr |
| Financing cash flowCash from Financing Activity | -₹157 Cr |
| Change in cashNet Cash Flow | -₹24 Cr |
Learn while you research
Academy chapters picked for JUBILANT PHARMOVA LIMITED and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read